Navigation Links
Premature ejaculation spray enables men to last 6 times longer after penetration
Date:4/6/2009

Men with premature ejaculation who used a topical spray five minutes before intercourse were able to delay their orgasm six times longer than normal, according to a study in the April issue of BJU International.

Three hundred men with clinically diagnosed lifelong premature ejaculation (PE) from 31 centres in the UK, Czech Republic, Hungary and Poland, were randomised into two groups. Two hundred used the PSD502 spray, which contains 7.5mg of lidocaine and 2.5mg of prilocaine, and 100 used a placebo spray with no active ingredients.

Every time they had intercourse during the three-month study period, each couple measured the time from vaginal penetration to ejaculation with a stopwatch. The men were asked to abstain from sexual activity or masturbation for 24 hours before each recorded encounter.

The time from penetration to ejaculation increased from an average of 0.6 minutes to 3.8 minutes in the medicated group and to just 1.1 minutes in the placebo group.

When these figures were adjusted to take account of any variations between the two groups, these showed that the treatment group were able to last 6.3 times longer after penetration when they used the spray. The placebo group lasted 1.7 times longer.

"Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy" says lead researcher Professor W Wallace Dinsmore from the Royal Victoria Hospital, Belfast, UK.

The research team used the evidence-based definition of lifelong PE developed by the International Society for Sexual Medicine to select their study subjects. This states that ejaculation occurs within about one minute of vaginal penetration in the majority of encounters.

"Because this definition was only launched in 2008, studies have yet to determine the prevalence of lifelong PE in the male population" says Professor Dinsmore. "But previous research suggests that as many as 40% of men will experience premature ejaculation at some time in their lives."

The 300 men who took part in the phase three, multicentre, double-blind, randomised study had an average age of 35. The majority had used other treatments before, the most common being oral antidepressants.

After three months of treatment the researchers reported that:

  • 90% of the men in the treatment group were able to delay ejaculation for more than one minute following vaginal penetration, compared with 54% in the placebo group.

  • 74% of men in the treatment group managed to last more than two minutes before ejaculation, compared with 22% in the placebo group.

  • 62% of men in the treatment group said their orgasms were 'good' or 'very good' after three months, compared with 20% before the study started. The figures for the placebo group were slightly lower at the end (19%) than at the start (21%).

  • 66% of men in the treatment group said the medication was 'good' or 'excellent' compared with 15% in the placebo group.

  • A significantly higher percentage of the patients and partners in the treatment group reported improvements when it came to perceived control, personal distress, satisfaction with sexual intercourse and interpersonal difficulties.

  • There were no serious adverse events reported during the study. Adverse treatment-related reactions were reported by five men and six women from the treatment group and one man from the placebo group. The most common problems were loss of erection and a burning sensation in the vagina.

"Our study shows that when the PSD502 spray was applied to the man's penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation" says Professor Dinsmore.

"It was well tolerated by both patients and their partners, with no systemic side effects and a low incidence of localised effects and was rated favourably by the majority of users.

"We believe that this shows that PSD502 offers significant advantages over other therapies being developed for the treatment of premature ejaculation."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New P.E. Drug Approved In Europe While Premature Ejaculation Cure Remains Out of Reach to American Men
2. Medical Costs for One Premature Baby Could Cover a Dozen Healthy Births
3. Medical costs for one premature baby could cover a dozen healthy births
4. Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes
5. UT Southwestern teaching hospital halves its rate of premature births, researchers find
6. Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
7. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
8. DHA Hailed as Breakthrough Treatment for Lowering Risk of Developmental Disorders in Premature Infants; Animi-3(R) Prescribed to Women Who Are Not Eating Fish
9. La Rabida Children's Hospital's 13th Annual Symposium to Discuss Outcomes of Premature Birth
10. Premature babies have altered sensory responses in later life
11. Stanford/Packard study shows no benefit from drug widely used to prevent premature births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... Center for Autism ... diagnosed with autism spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering ... analysis (ABA) is key to providing effective treatment for individuals with ASD. Now, ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast ... Hung to the company´s Board of Directors. , “We are honored to ... an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge ...
(Date:2/9/2016)... ... ... Dr. Rassouli, cosmetic dentist in Orange County , is now offering ... procedures in dentistry today, but the cost often leads to patients looking to less ... whitening-related damage. For a limited time, Dr. Rassouli is offering this special whitening package ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , Feb. 9, 2016  The Parenteral Drug ... professionals developing and manufacturing sterile drug products, today ... Regulatory Guidance Comparison – With link to Comparison ... issued by the U.S. FDA, the EU, the ... --> --> ...
(Date:2/8/2016)... , Feb.8, 2016 Cardiovascular Surgery ... Summary GlobalData,s Medical Devices sector report, "Cardiovascular ... provides an overview of Cardiovascular Surgery Devices currently ... --> The report provides comprehensive information ... the products at various stages of development. The ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , ... and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that they ... development and commercialization rights for OPA-15406 in the U.S. ... also provides manufacturing rights.  OPA-15406 is a topical, non-steroidal ... atopic dermatitis. --> --> ...
Breaking Medicine Technology: